RobertC, while Avid may end up benefiting as a CMO by manufacturing products for other biotechs getting to this emerging Biosimilars arena, I’m most excited about Peregrine’s own Biosimilar products, as selected by R.Garnick and Team Peregrine. Mkt. Approval of a Biosimilar product (or 2!) with Peregrine’s name on it is where the big payoff is…
As Rob said in the 7-14-10 CC: “We’ve been working equally hard I think on the Biosimilars program and really have made an astonishing amount of progress in an area, which as you can imagine is quite convoluted and difficult. I think we’re nearing our final decisions as to which candidates to bring forward, and really probably our next step will be to solidify our final decision, and then begin discussions with the FDA about how to proceed forward with this program because as you know, the FDA now has under the Patient Protection Health Care Act that was signed into law in March, and that was a pathway for biosimilars in the U.S. and we plan to take full advantage of that pathway as soon as possible. So, a very exciting project actually.” http://tinyurl.com/3a4p66c
Market Data 
Markets 
AI
